Free Trial

Frazier Life Sciences Management L.P. Buys 628,251 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

NewAmsterdam Pharma logo with Medical background

Frazier Life Sciences Management L.P. increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 5.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,855,194 shares of the company's stock after buying an additional 628,251 shares during the quarter. NewAmsterdam Pharma accounts for 8.6% of Frazier Life Sciences Management L.P.'s portfolio, making the stock its 2nd biggest holding. Frazier Life Sciences Management L.P. owned approximately 14.28% of NewAmsterdam Pharma worth $213,396,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in NAMS. Banque Cantonale Vaudoise acquired a new stake in NewAmsterdam Pharma during the second quarter valued at approximately $38,000. Quarry LP boosted its holdings in NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company's stock valued at $108,000 after purchasing an additional 6,247 shares in the last quarter. Barclays PLC boosted its holdings in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after purchasing an additional 7,199 shares in the last quarter. Bellevue Group AG acquired a new stake in NewAmsterdam Pharma during the third quarter valued at approximately $128,000. Finally, XTX Topco Ltd acquired a new stake in NewAmsterdam Pharma during the third quarter valued at approximately $187,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the company's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60. Following the transaction, the insider now owns 11,812,033 shares of the company's stock, valued at approximately $295,537,065.66. This represents a 0.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Louise Frederika Kooij sold 45,000 shares of the company's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The disclosure for this sale can be found here. Insiders have sold 86,803 shares of company stock valued at $1,755,307 in the last three months. 19.50% of the stock is owned by corporate insiders.

NewAmsterdam Pharma Stock Up 41.4 %

Shares of NAMS traded up $7.67 on Tuesday, hitting $26.19. The company's stock had a trading volume of 9,269,791 shares, compared to its average volume of 343,651. NewAmsterdam Pharma has a fifty-two week low of $9.39 and a fifty-two week high of $26.36. The company has a 50 day moving average price of $19.91 and a 200 day moving average price of $18.53.

Analyst Ratings Changes

NAMS has been the topic of a number of recent research reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Piper Sandler reaffirmed an "overweight" rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Finally, Needham & Company LLC reissued a "buy" rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $33.80.

Get Our Latest Report on NAMS

NewAmsterdam Pharma Company Profile

(Free Report)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Read More

Institutional Ownership by Quarter for NewAmsterdam Pharma (NASDAQ:NAMS)

Should you invest $1,000 in NewAmsterdam Pharma right now?

Before you consider NewAmsterdam Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.

While NewAmsterdam Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?
SoundHound Stock Explodes Again – Is a Major Breakout Coming?
How Fintech Strategy at FinWise Bancorp and CEO Vision Are Driving 78% Gains

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines